Intelerad Medical Systems(tm), a leader in medical imaging PACS, RIS and workflow solutions, today announced that the United States Department of Veterans Affairs (VA) has selected IntelePACS(r) as the picture archiving and communications system (PACS) for their National Teleradiology Program (NTP).

Treatment with neurological resection and carmustine wafers improved the cognitive trajectory, particularly memory and executive function, of patients with brain metastases according to a study published in the November issue of Cancer.

Risk scores computed by a new support vector machine (SVM) model that works with bilateral mammographic feature asymmetry could predict a woman’s near-term risk of developing breast cancer, according to a study published in the December issue of Academic Radiology.

A new method for predicting time to full-time care, nursing home residence, or death for patients with Alzheimer’s disease has been validated by a Columbia University Medical Center (CUMC) research team, as reported by the CUMC Newsroom on Nov. 7.

FDG uptake rose substantially in PET/CT scans of patients with higher levels of C-reative protein in their carotid arteries, pinpointing a potential biomarker for cardiovascular disease, according to an article published online Oct. 31 in the Journal of Nuclear Medicine.

Patients with traumatic brain injury (TBI) were found to have increased deposits of β-Amyloid (Aβ) plaques, a signature of Alzheimer Disease (AD), in some areas of the brain, according to a study published online Nov. 11 in JAMA Neurology.

Salvage patients, those with colorectal metastases to the liver who do not to respond to both first and second lines of treatment, are responding significantly to radioembolization with Y-90 microspheres. The dual-action treatment has been shown to lead to more than 12 months of overall survival, according to a study published Nov. 1 in the Journal of Nuclear Medicine.

Given Imaging (NASDAQ: GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that Japan's Central Social Insurance Medical Council (Chuikyo) has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for Given Imaging's PillCam COLON. With this approval, Chuikyo established a reimbursement of 83,100 JPY, or roughly $840.00 USD (using current exchange rate), per capsule that is scheduled to go into effect on January 1, 2014. This decision follows regulatory clearance of PillCam COLON in July of this year by Japan's Pharmaceuticals & Medical Devices Agency (PMDA). The MHLW will determine the final indication for use for PillCam COLON in December as well as the amount for the professional fee.